[go: up one dir, main page]

MX346557B - Moleculas de union a seroalbuminae. - Google Patents

Moleculas de union a seroalbuminae.

Info

Publication number
MX346557B
MX346557B MX2015004831A MX2015004831A MX346557B MX 346557 B MX346557 B MX 346557B MX 2015004831 A MX2015004831 A MX 2015004831A MX 2015004831 A MX2015004831 A MX 2015004831A MX 346557 B MX346557 B MX 346557B
Authority
MX
Mexico
Prior art keywords
serum albumin
binding molecules
albumin binding
relates
binds
Prior art date
Application number
MX2015004831A
Other languages
English (en)
Inventor
L Gosselin Michael
Fabrizio David
F Swain Joanna
S Mitchell Tracy
Camphausen Ray
T Cload Sharon
Furfine Eric
E Morin Paul
Mukherjee Ranjan
I Taylor Simeon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX346557B publication Critical patent/MX346557B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)

Abstract

La presente invención se refiere a una proteína tipo anticuerpo que se basa en el dominio de fibronectina tipo III a la décima (10Fn3) que se une a seroalbúmina. También, moléculas de fusión que comprenden una 10Fn3 de unión a seroalbúmina ligada a una proteína heteróloga para usar en aplicaciones terapéuticas y de diagnóstico.
MX2015004831A 2010-05-03 2011-05-03 Moleculas de union a seroalbuminae. MX346557B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33067210P 2010-05-03 2010-05-03
US13/098,851 US8969289B2 (en) 2010-05-03 2011-05-02 Serum albumin binding molecules
PCT/US2011/034998 WO2011140086A2 (en) 2010-05-03 2011-05-03 Serum albumin binding molecules

Publications (1)

Publication Number Publication Date
MX346557B true MX346557B (es) 2017-03-24

Family

ID=44628186

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015004831A MX346557B (es) 2010-05-03 2011-05-03 Moleculas de union a seroalbuminae.
MX2012012800A MX2012012800A (es) 2010-05-03 2011-05-03 Moleculas de union a seroalbuminae.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012012800A MX2012012800A (es) 2010-05-03 2011-05-03 Moleculas de union a seroalbuminae.

Country Status (21)

Country Link
US (4) US8969289B2 (es)
EP (1) EP2566888A2 (es)
JP (3) JP5876872B2 (es)
KR (1) KR101854931B1 (es)
CN (2) CN107698682A (es)
AR (1) AR081459A1 (es)
AU (1) AU2011248273B2 (es)
BR (1) BR112012028162A2 (es)
CA (1) CA2798510A1 (es)
CL (1) CL2012003077A1 (es)
CO (1) CO6630173A2 (es)
EA (1) EA029334B1 (es)
IL (1) IL222832A0 (es)
MX (2) MX346557B (es)
PE (1) PE20130593A1 (es)
SG (2) SG185091A1 (es)
TN (1) TN2012000518A1 (es)
TW (1) TW201138808A (es)
UY (1) UY33366A (es)
WO (1) WO2011140086A2 (es)
ZA (1) ZA201209091B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
PT2068909E (pt) 2007-03-30 2012-07-04 Ambrx Inc Polipéptidos fgf-21 modificados e suas utilizações
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
CN105727261A (zh) * 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
US9139629B2 (en) * 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
WO2012116264A1 (en) 2011-02-24 2012-08-30 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
US9403891B2 (en) * 2011-03-10 2016-08-02 New York University Methods and compositions for modulating TNF/TNFR signaling
HUE033008T2 (hu) 2011-04-13 2017-11-28 Bristol Myers Squibb Co FC fúziós proteinek, amelyek tartalmaznak új linkereket
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2729481B1 (en) * 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CA3095010A1 (en) 2012-02-21 2013-08-29 Cytonics Corporation Systems, compositions, and methods for transplantation
HUE067383T2 (hu) 2012-09-13 2024-10-28 Bristol Myers Squibb Co Fibronektin alapú, myostatinhoz kötõ állványdomén-fehérjék
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2953968B1 (en) * 2013-02-06 2018-07-25 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
ES2751735T3 (es) 2013-02-12 2020-04-01 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EA201591700A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
EP3024492A2 (en) 2013-07-25 2016-06-01 Novartis AG Bioconjugates of synthetic apelin polypeptides
CN103550790B (zh) * 2013-11-04 2016-01-27 上海交通大学医学院附属瑞金医院 骨膜蛋白抗体及其在药物制备中的应用
AU2014352962B2 (en) 2013-11-20 2019-11-07 Regeneron Pharmaceuticals, Inc. APLNR modulators and uses thereof
EP3129401B1 (en) * 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
CN106102767B (zh) * 2014-03-27 2021-08-10 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
EP3412302B1 (en) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
ME03806B (me) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
MX2017006530A (es) 2014-11-25 2017-08-10 Bristol Myers Squibb Co Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen.
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
EP3247405B1 (en) 2015-01-23 2019-07-17 Novartis AG Synthetic apelin fatty acid conjugates with improved half-life
US10849992B1 (en) * 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
SG11201708441RA (en) * 2015-04-24 2017-11-29 Viiv Healthcare Uk (No 5) Ltd Polypeptides targeting hiv fusion
WO2016197975A1 (en) * 2015-06-12 2016-12-15 Yen-Ta Lu Methods and polypeptides for modulation of immunoresponse
WO2017024137A1 (en) * 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
WO2017053617A1 (en) 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
EP3442997A2 (en) * 2016-04-15 2019-02-20 Indiana University Research & Technology Corporation Fgf21 c-terminal peptide optimization
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
JP7111627B2 (ja) 2016-06-03 2022-08-02 ヤンセン バイオテツク，インコーポレーテツド 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
CN106110325A (zh) * 2016-06-08 2016-11-16 上海朗安生物技术有限公司 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用
EA201990067A1 (ru) * 2016-06-21 2019-07-31 Янссен Байотек, Инк. Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
CN107693775A (zh) * 2016-08-08 2018-02-16 中国人民解放军沈阳军区总医院 Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途
EP3512541A1 (en) * 2016-09-14 2019-07-24 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
US11248022B2 (en) 2017-03-08 2022-02-15 The Regents Of The University Of Michigan Glypican-3 peptide reagents and methods
EP3626734A4 (en) 2017-03-16 2020-12-02 Shenzhen Institutes of Advanced Technology ENERGY METABOLISM REGULATORY POLYPEPTIDE AND ASSOCIATED USES
WO2018165933A1 (zh) * 2017-03-16 2018-09-20 深圳先进技术研究院 调节糖代谢的多肽及其用途
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2018301412A1 (en) * 2017-07-11 2020-01-30 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
CN109957005B (zh) * 2017-12-22 2021-04-20 深圳先进技术研究院 一种代谢素多肽人工抗原及其制备方法、抗体以及应用
CN109957006B (zh) * 2017-12-22 2021-04-20 深圳先进技术研究院 一种代谢素多肽人工抗原以及抗体和应用
EP3806889A4 (en) * 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
KR102273123B1 (ko) * 2018-10-24 2021-07-05 한국과학기술원 인간 혈장 알부민에 특이적으로 결합하는 신규한 폴리펩티드 및 이의 용도
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
CN109821012A (zh) * 2019-04-08 2019-05-31 河南师范大学 一种用于治疗代谢疾病的药物组合物及其缓释微球制剂
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CN111965356B (zh) * 2019-11-28 2023-09-08 上海荣盛生物药业股份有限公司 巯基还原组合物及荧光微球层析试纸和应用
CN113092772A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液黏连蛋白亚组sa-2及其多肽片段在过敏性疾病中的应用
CN111521812B (zh) * 2019-12-25 2023-02-17 瑞博奥(广州)生物科技股份有限公司 视神经脊髓炎谱系疾病生物标记物组及其应用和蛋白芯片、试剂盒
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113495147A (zh) * 2020-03-19 2021-10-12 首都医科大学附属北京世纪坛医院 尿液α2-巨球蛋白及其多肽片段在妊娠糖尿病中的应用
AU2021280623B9 (en) * 2020-05-27 2024-03-14 Sciwind Biosciences Co., Ltd. Interleukin 29 mutant protein
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
EP4171611A4 (en) * 2020-07-30 2024-10-02 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
CN112321720A (zh) * 2020-11-05 2021-02-05 无锡和邦生物科技有限公司 一种艾塞那肽人血清白蛋白融合蛋白的纯化方法
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
CN115385998A (zh) * 2021-04-13 2022-11-25 杭州先为达生物科技有限公司 稳定的iii型干扰素蛋白及其融合蛋白
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
CN117586423A (zh) * 2021-07-14 2024-02-23 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
CN114288414A (zh) * 2021-12-07 2022-04-08 深圳先进技术研究院 一种跨血脑屏障的多肽及其衍生物和应用
CN114306630A (zh) * 2021-12-07 2022-04-12 深圳先进技术研究院 一种靶向脑瘤的多肽及其衍生物和应用
EP4477665A1 (en) 2022-02-10 2024-12-18 AffyXell Therapeutics Co., Ltd. Stefin a protein variants specifically binding to cd40l, and uses thereof
WO2023183932A2 (en) * 2022-03-25 2023-09-28 New York University Monobodies binding to intercellular adhesion molecule 2 (icam-2)
CN114432429A (zh) * 2022-04-12 2022-05-06 中国人民解放军军事科学院军事医学研究院 一种预防或治疗骨关节炎的活性分子及其应用
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
CN115433776B (zh) * 2022-09-30 2023-12-22 中国医学科学院阜外医院 Ccn3在调控血管平滑肌细胞钙化中的应用
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用
WO2024153195A1 (en) * 2023-01-18 2024-07-25 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of fusion polypeptides and methods of uses thereof
TW202432577A (zh) * 2023-02-10 2024-08-16 美商拜奧海芬治療學有限公司 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
WO2024200987A1 (en) 2023-03-31 2024-10-03 Avacta Life Sciences Limited Tnfr2 binding polypeptides and methods of use
FR3147292A1 (fr) 2023-03-31 2024-10-04 Affyxell Therapeutics Co., Ltd. Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
US20240409583A1 (en) * 2023-05-22 2024-12-12 Kaida Biopharmaceuticals, Inc. Antagonist fusion polypeptides
GB202308304D0 (en) 2023-06-02 2023-07-19 Univ Ulster A fusion peptide for activation of the apj and/or glp-1 receptors

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
WO1992002536A1 (en) 1990-08-02 1992-02-20 The Regents Of The University Of Colorado Systematic polypeptide evolution by reverse translation
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5773574A (en) 1990-12-03 1998-06-30 The Scripps Research Institute Polypeptides for promoting cell attachment
US5235041A (en) 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
AU2313392A (en) 1991-08-01 1993-03-02 University Research Corporation Systematic polypeptide evolution by reverse translation
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
SG52542A1 (en) 1993-03-29 1998-09-28 Univ Cincinnati Analogs of peptide yy and uses thereof
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5559000A (en) 1995-01-18 1996-09-24 The Scripps Research Institute Encoded reaction cassette
DE19646372C1 (de) 1995-11-11 1997-06-19 Evotec Biosystems Gmbh Genotyp und Phänotyp koppelnde Verbindung
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
EP1477561B1 (en) 1996-10-17 2008-12-10 Mitsubishi Chemical Corporation Molecule assigning genotype to phenotype and use thereof
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
EP0971946B1 (en) 1997-01-21 2006-07-05 The General Hospital Corporation Selection of proteins using rna-protein fusions
US5830434A (en) 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
DE69933369D1 (en) 1998-04-03 2006-11-09 Compound Therapeutics Inc Adressierbare protein arrays
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CN101073668A (zh) 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ES2284508T3 (es) 1999-07-27 2007-11-16 Adnexus Therapeutics, Inc. Procedimientos de ligadura de aceptador de peptidos.
AU4445601A (en) 2000-03-31 2001-10-08 Centre National De La Recherche Scientifique-Cnrs Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
WO2001096559A2 (en) 2000-06-15 2001-12-20 Board Of Regents The University Of Texas System Regulatable, catalytically active nucleic acids
EP1301538B1 (en) 2000-07-11 2015-12-09 Research Corporation Technologies, Inc Artificial antibody polypeptides
AU2002213251B2 (en) 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
EP1572718A4 (en) 2001-04-04 2006-03-15 Univ Rochester ALPHA NU BETA-3 INTEGRIN BINDING POLYPEPTIDE ANTIBODY AND THEIR USE
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
AU2002342672A1 (en) 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2003286624B2 (en) 2002-10-23 2008-11-13 Bristol-Myers Squibb Company Methods for treating viral infection using IL-28 and IL-29
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AP2008004418A0 (en) 2005-10-07 2008-04-30 Univ California Nucleic acids encoding modified cytochrome p450 enzyme and methods of use thereof
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
ZA200807228B (en) 2006-02-24 2009-11-25 Chiesi Farma Spa Anti-amyloid immunogenic compositions, methods and uses
CN101426810A (zh) 2006-04-21 2009-05-06 特朗斯吉恩股份有限公司 基于hpv-18的乳头瘤病毒疫苗
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
CA2666507A1 (en) 2006-10-16 2008-04-24 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona A Cting For And On Behalf Of Arizona State University Synthetic antibodies
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
US20100166747A1 (en) 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
EP2222846B1 (en) 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
CN101883578A (zh) 2007-08-20 2010-11-10 百时美施贵宝公司 Vefr-2抑制剂用于治疗转移癌的用途
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
WO2009073115A1 (en) 2007-11-28 2009-06-11 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
JP2011507529A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｍ１３ファージのｐＩＸへの融合を介する代替の足場タンパク質融合ファージ提示
KR20100111283A (ko) 2007-12-27 2010-10-14 노파르티스 아게 개선된 피브로넥틴계 결합 분자 및 그들의 용도
WO2009102431A1 (en) 2008-02-12 2009-08-20 Certusview Technologies, Llc Searchable electronic records of underground facility locate marking operations
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
KR20110021832A (ko) 2008-05-02 2011-03-04 노파르티스 아게 개선된 피브로넥틴­기재 결합 분자 및 그의 용도
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
JP5985826B2 (ja) 2008-12-16 2016-09-06 ノバルティス アーゲー 酵母ディスプレイ系
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2464663A4 (en) 2009-08-13 2013-05-29 Massachusetts Inst Technology MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
EA201270713A1 (ru) * 2010-02-18 2013-01-30 Бристол-Майерс Сквибб Компани Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
US9249508B2 (en) 2010-03-14 2016-02-02 Mark S. Braiman Bromine-sensitized solar photolysis of carbon dioxide
CA2796338C (en) * 2010-04-13 2020-03-24 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP2571531B1 (en) 2010-04-30 2016-06-22 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
EP3222631A3 (en) 2010-07-30 2017-11-22 Novartis AG Fibronectin cradle molecules and libraries thereof
CN103380143B (zh) 2010-12-22 2016-01-06 百时美施贵宝公司 结合il-23的基于纤连蛋白的支架结构域蛋白质
HUE033008T2 (hu) 2011-04-13 2017-11-28 Bristol Myers Squibb Co FC fúziós proteinek, amelyek tartalmaznak új linkereket
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
KR102142385B1 (ko) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
EP3129401B1 (en) 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
WO2017053617A1 (en) * 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains

Also Published As

Publication number Publication date
US20190203248A1 (en) 2019-07-04
JP5876872B2 (ja) 2016-03-02
WO2011140086A3 (en) 2012-09-13
AR081459A1 (es) 2012-09-05
EA029334B1 (ru) 2018-03-30
UY33366A (es) 2011-10-31
US9540424B2 (en) 2017-01-10
AU2011248273A1 (en) 2012-12-20
CL2012003077A1 (es) 2013-03-22
AU2011248273B2 (en) 2015-09-10
KR101854931B1 (ko) 2018-05-04
WO2011140086A2 (en) 2011-11-10
CO6630173A2 (es) 2013-03-01
CN103003301A (zh) 2013-03-27
CN103003301B (zh) 2016-09-21
US20150152147A1 (en) 2015-06-04
JP2018057368A (ja) 2018-04-12
MX2012012800A (es) 2012-12-17
JP2013531477A (ja) 2013-08-08
SG10201503366XA (en) 2015-06-29
US20110305663A1 (en) 2011-12-15
TW201138808A (en) 2011-11-16
KR20130097083A (ko) 2013-09-02
TN2012000518A1 (en) 2014-04-01
PE20130593A1 (es) 2013-05-12
EA201270775A1 (ru) 2013-07-30
US10934572B2 (en) 2021-03-02
US10221438B2 (en) 2019-03-05
JP2016106074A (ja) 2016-06-16
US20170145464A1 (en) 2017-05-25
EP2566888A2 (en) 2013-03-13
IL222832A0 (en) 2012-12-31
BR112012028162A2 (pt) 2020-10-13
SG185091A1 (en) 2012-12-28
CN107698682A (zh) 2018-02-16
CA2798510A1 (en) 2011-11-10
WO2011140086A9 (en) 2011-12-29
ZA201209091B (en) 2015-07-29
JP6219357B2 (ja) 2017-10-25
US8969289B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
TN2012000518A1 (en) Serum albumin binding molecules
MX2016011580A (es) Dominios de fibronectina tipo iii que se unen a albumina de suero.
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
MX2013015324A (es) Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos.
EA201391564A1 (ru) Полипептиды антитела, которые антагонизируют cd40
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
PT2723771T (pt) Proteínas de ligação à albumina sérica
IN2013MN02441A (es)
MX357193B (es) Moleculas de union anti-alfa sinucleina.
WO2014165093A3 (en) Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
MX353382B (es) Moleculas de union polipeptido de larga duracion.
TN2011000225A1 (en) Bispecific egfr/igfir binding molecules
IN2014CN00437A (es)
MX2010011957A (es) Moleculas de union basadas en fibronectina mejoradas y usos de las mismas.
IN2012DN05169A (es)
MX2012013807A (es) Proteina de fusion que tiene actividad de factor vii.
WO2013025846A3 (en) Transferrin-tumstatin fusion protein and methods for producing and using the same
EP2682406A4 (en) FUSION PROTEIN WITH ALBUMIN AND A RETINOL BINDING PROTEIN
MX2013014008A (es) Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).
WO2011156694A3 (en) Enrichment and purification of infectious prion proteins